Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer
Phase 2
Completed
- Conditions
- CancerOvarian Cancer
- Interventions
- Drug: recombinant interleukin-21Drug: caelyx (pegylated liposomal doxorubicin)
- First Posted Date
- 2007-08-31
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 10
- Registration Number
- NCT00523380
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Wiesbaden, Germany
Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma
Phase 3
Terminated
- Conditions
- DiabetesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Asthma
- Interventions
- First Posted Date
- 2007-08-30
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 10
- Registration Number
- NCT00523042
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Zilina, Slovakia
The Effect of Insulin Detemir on Blood Glucose Control in Taiwanese Patients With Type 2 Diabetes Failing on OAD
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2007-08-28
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 25
- Registration Number
- NCT00521690
Growth Hormone Treatment in Children Born Small for Gestational Age: Assessment of Satisfaction
Phase 4
Completed
- Conditions
- Small for Gestational AgeFoetal Growth Problem
- First Posted Date
- 2007-08-23
- Last Posted Date
- 2015-11-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 5
- Registration Number
- NCT00519844
Growth Hormone Deficiency in Adults (GHDA)
Phase 3
Completed
- Conditions
- Growth Hormone DisorderAdult Growth Hormone Deficiency
- First Posted Date
- 2007-08-22
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 121
- Registration Number
- NCT00519558
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2007-08-21
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 467
- Registration Number
- NCT00518882
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, Lugano, Switzerland
Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes
Phase 4
Terminated
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2007-08-01
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 23
- Registration Number
- NCT00509925
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Guildford, United Kingdom
Comparison of Insulin Detemir and NPH Insulin Given Once Daily in Ageing Subjects With Type 2 Diabetes
Phase 4
Terminated
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 86
- Registration Number
- NCT00506662
Comparison of Insulin Detemir Versus Insulin NPH on Weight Change in Overweight and Obese With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 277
- Registration Number
- NCT00504673
The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis
Phase 3
Terminated
- Conditions
- End-Stage Renal DiseaseChronic Kidney Disease
- Interventions
- Drug: placebo
- First Posted Date
- 2007-07-19
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 712
- Registration Number
- NCT00503698
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wolverhampton, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath